Hope for New Vaccines

Sarah Schlesinger: What we know now is how a lot of things don’t work. Right now is a very challenging time in HIV vaccine development because nothing has worked. And not only has nothing worked, but the most promising candidates we’ve recently found out haven’t worked. There was a trial that was being conducted by NIH and Merck with a vaccine that was using an adeno-viral vector. So adeno virus is a virus that causes like a cold. Colleagues of mine, I wasn’t involved in this trial, though when it was beginning to be worked on, I was wishing that I could have been, because it seemed so promising, take this virus that’s an attenuated adeno virus, and they genetically engineer it to express, in this case, three different genes from HIV.

It looked very promising. It was inducing immunity, and it was inducing immunity in some animal models and early phase human trials, and there was a large trial that was conducted the past few years. Unfortunately, last fall we found out not only did it not protect people from HIV, in a subset of people it made them more susceptible. And that’s really a horror, because it’s obviously very frustrating to test things that don’t work, but as a physician our primary responsibility is something called “first do no harm.” It’s a Hippocratic dictum of “primum non nocere.” So you might not help people. You might not cure them. You might not prevent something, but the last thing you want to do is hurt them. And so for a preventive vaccine to even have the specter of causing increased infection, was horrible. Now, it’s very important to make the distinction that the vaccine did not cause HIV.

So there were several polio vaccines, for instance, that were tested in the ‘30s that were made from live polio virus that actually gave children vaccine associated polio. That is not the case with any AIDS vaccines. All the vaccines that have been tested are very safe in that they have nothing from live HIV, nothing from human blood. They, themselves, have not given anybody a disease. It’s not clear how it happened, and it’s being worked on avidly by many colleagues, but it appears that certain people were made more susceptible, and they were people who had high antibody ties to the adeno virus, which is a vector. And what that means is not clear yet, but people are still working on it. So to make an HIV vaccine is very hard for a lot of reasons.


Question: What makes HIV different from other viruses?


Sarah Schlesinger: HIV is a chronic viral infection, so people who get infected are not only not protected from other strains of HIV, they’re not even protected from your own strain of HIV. And why that is a subject of a lot of investigation, and it may be that HIV has evolved to induce immunologic silence or tolerance. And that’s a kind of current thinking, and I think that that’s probably correct. But what that means is we don’t have the model of natural infection conferring protection to make a vaccine. And this is one of the reasons that there are some people who query if it’s even possible to make a vaccine for HIV, and they might be right. My view is, is that it’s easy to say why things won’t work, and this is the worst epidemic that hits mankind. There are 15,000 new infections everyday.

Eight thousand people are dying everyday. And so it’s a moral imperative to try. So even if the kind of classic vaccine, when you think of smallpox or polio, where you get sterilizing protection, if you will, may not be possible. Perhaps we can develop a vaccine that will reduce, not prevent infection, but prevent disease. And, in fact, when you look really carefully at most licensed vaccines, that’s what they do. You get a certain amount of replication of the virus, and then disease is prevented. When you think about it, what is it that we really want to prevent? It’s disease and death. So the natural infection issue is one. As I mentioned earlier, there’s no animal model. Only humans get HIV, so we don’t have a good animal model.

Nobody’s ever been protected by a vaccine, so we don’t even know what to measure in the blood. We have our favorite ideas. We know from our other vaccines, from smallpox, from tetanus, the sorts of things that one needs. We know you need neutralizing antibody. We know you need cytotoxic T-cells. We know you need helper T-cells, but which of those is the most critical? Whether you need them all, at what level you need them, nobody knows.

And so we end up having a terrible time knowing what even to move forward. So if we have 10 candidate vaccines, and candidate vaccine is a vaccine that’s not licensed. And even if we can test them in a small group of humans, how do we know which one is better? That’s yet another challenge. So those three challenges make it very hard to develop an HIV vaccine. And that isn’t even getting into the sort of the political and social challenges, which are complicated and myriad and probably you’ll have somebody else to address those.


Recorded on: June 10, 2008


The Rockefeller University Professor on the hunt for an AIDS cure.

  • Beethovan and Picasso are the perfect examples for mastering the creative process.
  • Behind each of their works are countless studies and sketches.
  • The lesson? Never erase anything, keep iterating, and find new paths to familiar destinations.

After death, you’re aware that you’ve died, say scientists

Some evidence attributes a certain neurological phenomenon to a near death experience.

Credit: Petr Kratochvil. PublicDomainPictures.net.
Surprising Science

Time of death is considered when a person has gone into cardiac arrest. This is the cessation of the electrical impulse that drive the heartbeat. As a result, the heart locks up. The moment the heart stops is considered time of death. But does death overtake our mind immediately afterward or does it slowly creep in?

Keep reading Show less
Big Think
Sponsored by Lumina Foundation

Upvote/downvote each of the videos below!

As you vote, keep in mind that we are looking for a winner with the most engaging social venture pitch - an idea you would want to invest in.

Lumina Foundation and Big Think have partnered to bring this entrepreneurial competition to life, and we hope you'll participate! We have narrowed down the competition to four finalists and will be announcing an audience's choice award and a judges' choice award in May.

The creator of the winning video — chosen by Big Think's audience, the Lumina Foundation, and an independent panel of experts (bios below) — will be flown to New York for a taping in the Big Think studio as a way to further promote their vision for a new, disruptive idea in post-secondary education.

Thank you to all of the contestants who spent time submitting applications, and best of luck to our final four competitors.

Finalist: Greater Commons - Todd McLeod

Greater Commons, founded by Todd McLeod and Andrew Cull, is an organization that helps people live happier, more successful and fulfilling lives through agile learning. The current education system is inefficient and exclusionary, in which many students who end up earning a degree, if at all, enter a career not related to their field of study. Greater Commons solves this problem and gap in post-high school secondary education in a variety of ways. Passionately and diligently, Great Commons helps others obtain skills, knowledge, wisdom, motivation, and inspiration so that they may live better lives.

Finalist: PeerFoward - Keith Frome

PeerForward is an organization dedicated to increasing the education and career success rates of students in low-income schools and communities by mobilizing the power of positive peer influence. PeerForward works with partner schools to select influential students as a part of a team, systemizing the "peer effect." Research in the fields of sociology of schools, social-emotional learning, adult-youth partnerships, and civic education demonstrates that students can have a positive effect on the academic outcomes of their peers. PeerForward is unique through its systemic solutions to post-secondary education.

Finalist: Cogniss - Leon Young

Cogniss combines technology and best practice knowledge to enable anyone to innovate and share solutions that advance lifelong learning. Cogniss is the only platform to integrate neuroscience, through which it solves the problem of access by providing a low-code platform that enables both developers and non-developers to build sophisticated education apps fast, and at a much lower cost. It addresses the uneven quality of edtech solutions by embedding research-based learning design into its software. App creators can choose from a rich set of artificial intelligence, game, social and data analytics, and gamification to build their perfect customized solution.

Finalist: Practera - Nikki James

Practera's mission is to create a world where everyone can learn through experience. Today's workplaces are increasingly dynamic and diverse, however, costly and time-consuming experiential learning is not always able to offer the right opportunities at scale. Many students graduate without developing the essential skills for their chosen career. Practera's team of educators and technologists see this problem as an opportunity to transform the educational experience landscape, through a CPL pedagogical framework and opportunities to apply students' strengths through active feedback.

Thank you to our judges!

Our expert judges are Lorna Davis, Dan Rosensweig, and Stuart Yasgur.

Lorna Davis is the Senior Advisor to Danone CEO and is a Global Ambassador for the B Corp movement. Lorna has now joined B-Lab, the non-for-profit that supports the B Corporation movement on an assignment to support the journey of large multi nationals on the path to using business as a force of good.

Dan Rosensweig joined Chegg in 2010 with a vision for transforming the popular textbook rental service into a leading provider of digital learning services for high school and college students. As Chairman and CEO of Chegg, Dan commits the company to fulfilling its mission of putting students first and helping them save time, save money and get smarter.

Stuart Yasgur leads Ashoka's Social Financial Services globally. At Ashoka, Stuart works with others to initiate efforts that have mobilized more than $500 million in funding for social entrepreneurs, engaged the G20 through the Toronto, Seoul and Los Cabos summits and helped form partnerships with leading financial institutions and corporations.

Again, thank you to our incredible expert judges.